New Drug Approvals
Follow New Drug Approvals on WordPress.com

FLAGS AND HITS

Flag Counter
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO

Archives

Categories

Join me on Linkedin

View Anthony Melvin Crasto Ph.D's profile on LinkedIn

Join me on Researchgate

Anthony Melvin Crasto Dr.

  Join me on Facebook FACEBOOK   ...................................................................Join me on twitter Follow amcrasto on Twitter     ..................................................................Join me on google plus Googleplus

MYSELF

DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 36Yrs Exp. in the feld of Organic Chemistry,Working for AFRICURE PHARMA as ADVISOR earlier with GLENMARK PHARMA at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, NO ADVERTISEMENTS , ACADEMIC , NON COMMERCIAL SITE, world acclamation from industry, academia, drug authorities for websites, blogs and educational contribution, ........amcrasto@gmail.com..........+91 9323115463, Skype amcrasto64 View Anthony Melvin Crasto Ph.D's profile on LinkedIn Anthony Melvin Crasto Dr.

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 37.7K other subscribers
DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with AFRICURE PHARMA, ROW2TECH, NIPER-G, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Govt. of India as ADVISOR, earlier assignment was with GLENMARK LIFE SCIENCES LTD, as CONSUlTANT, Retired from GLENMARK in Jan2022 Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 32 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri, etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him Open superstar worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 32 PLUS year tenure till date Feb 2023, Around 35 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 100 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 100 Lakh plus views on dozen plus blogs, 227 countries, 7 continents, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 38 lakh plus views on New Drug Approvals Blog in 227 countries......https://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc He has total of 32 International and Indian awards

Verified Services

View Full Profile →

Recent Posts

Bepirovirsen

October 21, 2026 2:34 am / Leave a comment


Bepirovirsen

CAS 1403787-62-1

NA SALT 1403787-62-1

FormulaC230H309N88O115P19S19
Molar mass7344.14 g·mol−1

FDA 2026, APPROVALS 2026, Hibsago, hepatitis B

To treat chronic hepatitis B virus infection in certain adults without cirrhosis, in combination with existing antiviral therapy

Bepirovirsen (sold as Hibsago) is a first-in-class antisense oligonucleotide injection developed by GSK and Ionis Pharmaceuticals to treat chronic hepatitis B (CHB). It acts as a potential functional cure by targeting viral RNA, reducing surface antigen levels, and stimulating the immune system.

What It Does & How It Works

  • Mechanism of Action: A non-GalNAc-conjugated antisense oligonucleotide that recognizes and destroys hepatitis B virus RNA, lowers viral protein production, and activates immune responses.
  • Functional Cure Definition: Achieves sustained HBV DNA suppression and undetectable hepatitis B surface antigen (HBsAg) for at least 24 weeks after stopping all treatments.
  • Clinical Trial Results: In the Phase 3 B-Well 1 and B-Well 2 trials, 19% to 24% of eligible patients achieved a functional cure and safely discontinued existing antiviral medications.

Regulatory Status & Approvals

  • United States: Approved by the FDA in October 2026 for use in certain adults without cirrhosis who have been on antiviral therapy for at least six months and have HBsAg levels of 3,000 IU/mL or less. It features a boxed warning for potential serious liver reactions and low platelet counts.
  • Japan: Approved as the first functional cure option for chronic hepatitis B under the brand name Hibsago.
  • Other Designations: Granted Breakthrough Therapy and Priority Review designations in China and SENKU designation in Japan.

Bepirovirsen, sold under the brand name Hibsago, is an antisense oligonucleotide gapmer developed to treat hepatitis B infection.[1]

PAT

WO2012145697

PAT

WO2024214041A1

https://patents.google.com/patent/WO2024214041A1/en

Bepirovirsen is an ASO currently in clinical evaluation for treating Chronic HBV infections. It is compound ISIS No. 505358 as disclosed in WO2012/145697. Bepirovirsen has 20 linked nucleosides and has a nucleobase sequence of 5′-GCAGAGGTGAAGCGAAGTGC- 3′ (SEQ ID NO: 1), and it includes: a gap segment consisting of ten linked deoxynucleosides, a 5′ wing segment consisting of 5 linked nucleosides, and a 3′ wing segment consisting of 5 linked nucleosides, wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment, wherein each nucleoside of each wing segment includes a 2′-O-methoxyethyl sugar, wherein each intemucleoside linkage is a phosphorothioate linkage, and wherein each cytosine is a 5 -methylcytosine. The CAS Registry Number of bepirovirsen is 1403787-62-1.

AHB-137 is an unconjugated ASO that is believed to have the same nucleobase sequence as bepirovirsen. AHB-137 is developed by Ausper Biopharma Co., Ltd. and is currently investigated in clinical studies for treating HBV infections. See WO2023/131098; Qiu, X. et al., “AHB-137, a novel and potent hepatitis B virus antisense oligonucleotide with a favorable preclinical pharmacokinetics and safety profile,” EASL 2023, Abstract No. SAT-178 (concluding that “the novel HBV ASO AHB-137 has demonstrated a favorable preclinical pharmacokinetics and safety profile”); Wu, X. et al., “AHB-137, a novel hepatitis B virus antisense oligonucleotide with substantially enhanced in vitro and in vivo antiviral activity,” EASL 2023, Abstract No. SAT-173 (concluding that “AHB-137 has more potent activity in reducing serum HBsAg than BPV [bepirovirsen] across multiple in vitro and in vivo HBV models, by reducing intrahepatic HBV RNA and HBsAg”).

ADVERTISEMENT

ANAX LABORATORIES

WEBSITE https://www.anaxlab.com/

Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences

Development Solutions, Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales

SEE MORE………Integrated Solutions, Manufacturing Solutions, Products,
Can’t Find? Let’s Connect

Phone : +91 897704 2010 /  +91 9177075735, Email : info@anaxlab.com

#MedicinalChemistry, #DrugDiscovery, #OrganicSynthesis, #ChemicalLibrary, #BuildingBlocks, #SARStudies, #ChemistryInnovation, #medchem, #Drugdevelopment, #Biotech, #Biotechnology, #AnaxLaboratories, #Pharma

str1

AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

wdt-16

join me on Linkedin

Anthony Melvin Crasto Ph.D – India | LinkedIn

join me on Researchgate

RESEARCHGATE

This image has an empty alt attribute; its file name is research.jpg

join me on Facebook

Anthony Melvin Crasto Dr. | Facebook

join me on twitter

Anthony Melvin Crasto Dr. | twitter

+919321316780 call whatsaapp

EMAIL. amcrasto@gmail.com

References

Mak, Lung-Yi; Hui, Rex Wan-Hin; Fung, James; Seto, Wai-Kay; Yuen, Man-Fung (2 November 2023). “Bepirovirsen (GSK3228836) in chronic hepatitis B infection: an evaluation of phase II progress”. Expert Opinion on Investigational Drugs. 32 (11): 971–983. doi:10.1080/13543784.2023.2277389. PMID 37902953. S2CID 264672407.

Clinical data
Trade namesHibsago
Other namesGSK3228836
Identifiers
IUPAC name
CAS Number1403787-62-1
UNIIZ87O6SM01N
ChEMBLChEMBL4650468
Chemical and physical data
FormulaC230H309N88O115P19S19
Molar mass7344.14 g·mol−1
SMILES
InChI

///////////////bepirovirsen, anax labs, FDA 2026, APPROVALS 2026, Hibsago, hepatitis B

#bepirovirsen, #anax labs, #FDA 2026, #APPROVALS 2026, #Hibsago, #hepatitis B

Bosmolisib

October 20, 2026 2:34 am / Leave a comment


Bosmolisib

CLICK https://newdrugapprovals.org/2026/01/09/bosmolisib/

Cenacitinib

October 19, 2026 2:25 am / Leave a comment


Cenacitinib

click https://newdrugapprovals.org/2026/01/15/cenacitinib/

Emestedastat

October 18, 2026 2:30 am / Leave a comment


Emestedastat

CLICK https://newdrugapprovals.org/2026/01/19/emestedastat/

Enrupatinib

October 17, 2026 3:05 am / Leave a comment


Enrupatinib

CLICK https://newdrugapprovals.org/2026/01/20/enrupatinib/

Evetifator

October 17, 2026 2:32 am / Leave a comment


Evetifator

Evetifator

CLICK LINK https://newdrugapprovals.org/2026/01/22/evetifator/

Fanregratinib

October 16, 2026 8:56 am / Leave a comment


Fanregratinib

CLICK LINK https://newdrugapprovals.org/2026/01/23/fanregratinib/

Fosrolapitant

October 16, 2026 2:49 am / Leave a comment


Fosrolapitant

CLICK LINK https://newdrugapprovals.org/2026/01/25/fosrolapitant/

Tarvicopan

October 15, 2026 2:26 am / Leave a comment


Tarvicopan

CAS2378381-06-5

MW C24H22N2O4 MW 402.4 g/mol

2-[2-[[7-[2-(aminomethyl)-4-pyridinyl]-2-methyl-1-benzofuran-5-yl]methoxy]phenyl]acetic acid

[2-({7-[2-(aminomethyl)pyridin-4-yl]-2-methyl-1-benzofuran-5-yl}methoxy)phenyl]acetic acid
complement factor D inhibitor, MWL2DF9UJJ

Tarvicopan is an investigational small-molecule compound that acts as an inhibitor of complement factor D.

Mechanism and Clinical Context

  • Complement Factor D Inhibitor: It specifically targets factor D, a rate-limiting enzyme in the alternative pathway of the complement system. The complement system is a crucial part of the innate immune response, but its overactivation is linked to several autoimmune and inflammatory diseases.

PAT

US11370774,

Compound 112c

PAT

WO2019195720

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019195720&_cid=P11-MV8WTL-54517-1

Scheme-112

ADVERTISEMENT

ANAX LABORATORIES

WEBSITE https://www.anaxlab.com/

Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences

Development Solutions, Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales

SEE MORE………Integrated Solutions, Manufacturing Solutions, Products,
Can’t Find? Let’s Connect

Phone : +91 897704 2010 /  +91 9177075735, Email : info@anaxlab.com

#MedicinalChemistry, #DrugDiscovery, #OrganicSynthesis, #ChemicalLibrary, #BuildingBlocks, #SARStudies, #ChemistryInnovation, #medchem, #Drugdevelopment, #Biotech, #Biotechnology, #AnaxLaboratories, #Pharma

str1

AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

wdt-16

join me on Linkedin

Anthony Melvin Crasto Ph.D – India | LinkedIn

join me on Researchgate

RESEARCHGATE

This image has an empty alt attribute; its file name is research.jpg

join me on Facebook

Anthony Melvin Crasto Dr. | Facebook

join me on twitter

Anthony Melvin Crasto Dr. | twitter

+919321316780 call whatsaapp

EMAIL. amcrasto@gmail.com

References

////////tarvicopan, anax labs, complement factor D inhibitor, MWL2DF9UJJ

#tarvicopan, #anax labs, #complement factor D inhibitor, #MWL2DF9UJJ

Suraxavir marboxil

October 13, 2026 2:29 am / Leave a comment


Suraxavir marboxil

CAS 2364589-86-4

MFC29H25F2N3O7S MW597.6 g/mol

[(3R)-2-[(11S)-7,8-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-9,12-dioxospiro[5-oxa-1,2,8-triazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-6,1′-cyclopropane]-11-yl]oxymethyl methyl carbonate

[(3R)-2-[(11S)-7,8-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-9,12-dioxospiro[5-oxa-1,2,8-triazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-6,1′-cyclopropane]-11-yl]oxymethyl methyl carbonate

({(12’aR)-12′-[(11S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl]-6′,8′-dioxo-6′,8′,12′,12’a-tetrahydro-1’H,4’H-spiro[cyclopropane-1,3′-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin]-7′-yl}oxy)methyl methylcarbonate
antiviral, GP 681, Jiangxi Qingfeng Pharmaceutical, influenza A, INFLUENZA B, Cap-dependent endonuclease-IN-3, A72V8WPZ9F

Suraxavir marboxil (GP681) is an oral antiviral prodrug developed by Jiangxi Qingfeng Pharmaceutical for treating acute, uncomplicated influenza A and B virus infections.

Key Details

  • Mechanism of Action: It converts into its active metabolite, GP1707D07, which acts as a cap-dependent endonuclease (CEN) inhibitor by targeting the polymerase acidic (PA) protein subunit of the influenza virus RNA polymerase. This stops viral gene transcription and replication.
  • Administration: Designed as a single-dose oral therapy (typically evaluated at 40 mg).
  • Efficacy: In phase 3 clinical trials, a single dose administered within 48 hours of symptom onset reduced the median time to symptom alleviation to 42.0 hours (compared to 63.0 hours for placebo) and rapidly lowered viral load.
  • Safety Profile: Adverse events are mostly mild to moderate and comparable to placebo, with low rates of acquired resistance (such as I38T PA variants).
  • OriginatorJiangxi Qingfeng Pharmaceutical
  • ClassAntivirals; Carbonates; Cyclopropanes; Dibenzothiepins; Ethers; Fluorobenzenes; Ketones; Morpholines; Pyridones; Small molecules; Spiro compounds; Triazines
  • Mechanism of ActionRNA-dependent RNA polymerase inhibitors
  • RegisteredInfluenza virus infections
  • 28 Nov 2025Capital Medical University initiates enrolment in a phase III trial for Influenza virus infections (In children, In adults, In the elderly) in China (PO) (NCT07236814)
  • 01 Aug 2025Jiangxi Kerui Pharmaceutical plans a phase III trial for Influenza virus infections (In Children) in August 2025 (PO, suspension) (NCT07113392)
  • 31 Mar 2025Chemical structure information added.

PAT

US20230144122

https://patentscope.wipo.int/search/en/detail.jsf?docId=US397715831&_cid=P20-MV61ZK-74389-1

 Preparation of Compound of formula (10): Compound of formula (11) (388 mg, 1 mmol) was dissolved in 3 mL dichloromethane and added with 1 mL trifluoroacetic acid, and the mixture was stirred at room temperature for 3 hours. TLC showed the reaction was complete, and the mixture was added with 3N sodium hydroxide solution to adjust pH=9-10. The mixture was extracted with dichloromethane, and organic phases were merged, washed with saturated salt solution, dried, and concentrated to give 270 mg solid, which was directly used in the next step.
      Preparation of Compound of formula (8): Compound of formula (9) (1.0 g, 7.8 mmol) was dissolved in 10 mL anhydrous tetrahydrofuran, and dropwise added with 2.5M n-butyllithium solution (3.1 mL, 7.8 mmol) slowly at −78° C. and under nitrogen protection. After addition, the mixture was stirred and reacted at the temperature for 2 hours. Then allyl formate (0.94 g, 7.8 mmol) was dropwise added. After addition, the mixture was stirred and reacted for 2 hours, and TLC showed the raw materials were substantially completely reacted, and then the reaction mixture was poured into saturated ammonium chloride solution to quench, and then extracted with ethyl acetate (15 mL×3). The organic phases were merged, dried over anhydrous sodium sulfate, and concentrated to dry to give 1.65 g oily product.
      Preparation of Compound of formula (7): Compound of formula (8) (1.65 g, 7.8 mmol) was dissolved in 15 mL anhydrous tetrahydrofuran, and dropwise added with 1M diisobutylaluminum hydride solution (11.7 mL, 11.7 mmol) slowly at −78° C. and under nitrogen protection. After addition, the mixture was stirred and reacted at the temperature for 2 hours. TLC showed the raw materials were substantially completely reacted, and then the reaction mixture was poured into saturated potassium sodium tartrate solution to quench, and then extracted with ethyl acetate (20 mL×3). The organic phases were merged, dried over anhydrous sodium sulfate, and concentrated to dry to give 1.57 g oily product.
      Preparation of Compound of formula (6): Compound of formula (7) (1.57 g, 7.4 mmol) was dissolved in 15 mL methanol, and p-toluenesulfonic acid monohydrate (140 mg, 0.74 mmol) was added, and the mixture was stirred at room temperature overnight. TLC showed the raw materials were substantially completely reacted, and then the mixture was added with saturated sodium bicarbonate solution to adjust to be neutral, and concentrated. The residue was separated by column chromatography to give 0.86 g yellow oily product.
      Preparation of Compound of formula (5): Compound of formula (10) (270 mg, 0.94 mmol) and Compound of formula (6) (255 mg, 1.13 mmol) were dissolved in 5 mL acetonitrile. 1M solution of tin tetrachloride in dichloromethane (1.4 mL, 1.41 mmol) was added dropwise under nitrogen protection and at −20° C. After addition, the mixture was stirred and reacted at the temperature for 3 hours. The mixture was added with saturated sodium bicarbonate solution, stirred for 30 min, and stood to layer, and the aqueous phase was extracted with dichloromethane. The organic phases were merged, washed with saturated salt solution, dried, and concentrated to give 428 mg crude product.
      Preparation of Compound of formula (4): Compound of formula (5) (428 mg, 0.89 mmol) was dissolved in 5 mL tetrahydrofuran, and tetrakis(triphenylphosphine)palladium (104 mg, 0.09 mmol) and morpholine (774 mg, 8.9 mmol) were added and reacted at room temperature for 2 hours. The reaction was shown complete through TLC spot plate analysis. The mixture was concentrated, and the residue was separated by column chromatography to give 216 mg product.
      Preparation of Compound of formula (3): Compound of formula (4) (216 mg, 0.61 mmol) and Compound of formula (12) (242 mg, 0.92 mmol) were reacted at 100° C. for 3 hours in 3 mL solution of T 3P in ethyl acetate under airtight condition. The mixture was cooled, diluted with saturated NaHCO3, and then extracted with ethyl acetate. The organic phases were merged, dried and concentrated, and separated by column chromatography to give 200 mg crude product, which was separated by chiral column to give 40 mg product.
      Preparation of Compound of formula (2): Compound of formula (3) (40 mg, 0.067 mmol) and lithium chloride (20 mg, 0.48 mmol) were reacted at 100° C. for 3 hours in 1 mL DMA. After the reaction finished, the mixture was diluted with 10 mL water, and added with 2N hydrochloric acid to adjust pH to 3-4. The mixture was filtered, and the solid was pumped to dry to give 25 mg product. 1HNMR (400 MHz, CDCl 3) δ: 7.05-7.15 (m, 5H), 6.85 (m, 1H), 6.70 (d, 1H, J=7.6 Hz), 5.78 (d, 1H, J=7.6 Hz), 5.3 (m, 2H), 4.69 (d, 1H, J=6.8 Hz), 4.17 (d, 1H, J=14 Hz), 4.09 (d, 1H, J=14 Hz), 3.90 (m, 1H), 3.69 (m, 1H), 3.44 (d, 1H, J=15.2 Hz), 0.95 (m, 1H), 0.74 (m, 3H); ESI-MS m/z (M+H) + 510.1.
      Preparation of Compound of formula (1): Compound of formula (2) (40 mg, 0.08 mmol), chloromethyl methyl carbonate (25 mg, 0.2 mmol), potassium carbonate (28 mg, 0.2 mmol) and potassium iodide (3 mg, 0.02 mmol) were reacted at 60° C. for 5 hours in 1 mL N,N-dimethylacetamide. The reaction was shown complete through TLC spot plate analysis, the mixture was added with water to quench, and added with 1N diluted hydrochloric acid to adjust pH to 3-4. The solid was filtered, dried, and separated by column chromatography to give 35 mg product, which was the compound of formula (1), and the solid was analyzed to be amorphous and used as the starting material for preparing various crystal forms in subsequent embodiments. 1HNMR (400 MHz, DMSO-d6) δ: 7.40-7.42 (m, 2H), 7.25 (d, 1H, J=7.6 Hz), 7.15 (m, 1H), 7.10 (m, 1H), 7.00 (d, 1H, J=7.2 Hz), 6.84 (t, 1H, J=7.6 Hz), 5.75 (m, 4H), 5.43 (d, 1H, J=16.4 Hz), 4.57 (dd, 1H, J=3.2, 9.6 Hz), 3.96-4.03 (m, 3H), 3.73 (s, 3H), 3.51 (t, 1H, J=10.0 Hz), 3.41 (s, 1H), 0.75 (t, 2H, J=8.4 Hz), 0.50 (m, 2H); ESI-MS m/z (M+H) + 598.1.

PAT

US20190367517

https://patentscope.wipo.int/search/en/detail.jsf?docId=US278278529&_cid=P20-MV6251-78985-1

ADVERTISEMENT

ANAX LABORATORIES

WEBSITE https://www.anaxlab.com/

Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences

Development Solutions, Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales

SEE MORE………Integrated Solutions, Manufacturing Solutions, Products,
Can’t Find? Let’s Connect

Phone : +91 897704 2010 /  +91 9177075735, Email : info@anaxlab.com

#MedicinalChemistry, #DrugDiscovery, #OrganicSynthesis, #ChemicalLibrary, #BuildingBlocks, #SARStudies, #ChemistryInnovation, #medchem, #Drugdevelopment, #Biotech, #Biotechnology, #AnaxLaboratories, #Pharma

str1

AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

wdt-16

join me on Linkedin

Anthony Melvin Crasto Ph.D – India | LinkedIn

join me on Researchgate

RESEARCHGATE

This image has an empty alt attribute; its file name is research.jpg

join me on Facebook

Anthony Melvin Crasto Dr. | Facebook

join me on twitter

Anthony Melvin Crasto Dr. | twitter

+919321316780 call whatsaapp

EMAIL. amcrasto@gmail.com

References

///////////suraxavir marboxil, anax labs, antiviral, GP 681, Jiangxi Qingfeng Pharmaceutical, influenza A, INFLUENZA B, Cap-dependent endonuclease-IN-3, A72V8WPZ9F

#suraxavir marboxil, #anax labs, #antiviral, #GP 681, #Jiangxi Qingfeng Pharmaceutical, #influenza A, #INFLUENZA B, #Cap-dependent endonuclease-IN-3, #A72V8WPZ9F

Post navigation

← Older posts

DR ANTHONY MELVIN CRASTO

ANTHONY MELVIN CRASTO MY BLOGS......... ALL ABOUT DRUGS, WORLD DRUG TRACKER, MEDICINAL CHEM INTERNATIONAL, DRUG SYN INTERNATIONAL SCALEUP OF DRUGS,   MEDICINAL CHEM INTERNATIONAL, DRUG SYN INTERNATIONAL, SCALEUP OF DRUGS, EUREKAMOMENTS, and my new blog API SYNTHESIS INTERNATIONAL  
Follow New Drug Approvals on WordPress.com

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 37.7K other subscribers

ORGANIC SPECTROSCOPY

Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 

feedjit

Feedjit Live Blog Stats

DISCLAIMER

I , Dr A.M.Crasto is writing this blog to share the knowledge/views, after reading Scientific Journals/Articles/News Articles/Wikipedia. My views/comments are based on the results /conclusions by the authors(researchers). I do mention either the link or reference of the article(s) in my blog and hope those interested can read for details. I am briefly summarising the remarks or conclusions of the authors (researchers). If one believe that their intellectual property right /copyright is infringed by any content on this blog, please contact or leave message at below email address amcrasto@gmail.com. It will be removed ASAP